Romania - romania - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

abbvie s.r.l. - italia - clarithromycinum - compr. film. - 250mg - macrolide, lincosamide si streptogramine macrolide

Euroopan unioni - romania - EMA (European Medicines Agency)

mylan pharmaceuticals limited - clorhidratul de anagrelidă - trombocitmie, esențială - agenți antineoplazici - anagrelidă este indicat pentru reducerea numărului crescut de trombocite în risc de trombocitemie esențială (te) pacienții care nu tolerează terapia curentă sau a căror crescut de trombocite nu sunt reduse la un nivel acceptabil prin lor actuale de terapie. an at-risk patientan at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events.

Romania - romania - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

patheon france-bourgoin jalileu - franta - atomoxetinum - sol. orala - 4mg/ml - psihostimulante si nootrope simpatomimetice cu actiune centrala

Euroopan unioni - romania - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - respingerea grefei - imunosupresoare - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Euroopan unioni - romania - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - carcinom, pulmonar non-celulă mică - agenți antineoplazici - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Euroopan unioni - romania - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmologice - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Euroopan unioni - romania - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuclide imaging - produse radiofarmaceutice de diagnosticare - acest medicament este destinat exclusiv diagnosticului. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Euroopan unioni - romania - EMA (European Medicines Agency)

ucb pharma sa - certolizumab pegol - crohn boala - imunosupresoare - cimzia, in combination with methotrexate (mtx), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmard) including methotrexate, has been inadequate. cimzia poate fi administrat în monoterapie în caz de intoleranță la metotrexat sau atunci când tratamentul continuu cu metotrexat este inadecvat. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.

Euroopan unioni - romania - EMA (European Medicines Agency)

mylan pharmaceuticals limited - cinacalcet clorhidrat - hyperparathyroidism, secondary; hypercalcemia - homeostazia de calciu - tratamentul hiperparatiroidismului secundar (hpt) la pacienții cu boală renală în stadiu terminal (esrd) la terapia de dializă de întreținere. cinacalcet mylan poate fi folosit ca parte a unui regim terapeutic, inclusiv cu chelatori de fosfați și/sau analogi ai vitaminei d, după caz. reducerea hipercalcemiei la pacienții cu:paratiroide carcinomaprimary hpt pentru care parathyroidectomywould fie indicat pe baza nivelelor serice de calciu (astfel cum sunt definite în ghidurile de tratament relevante), dar în care paratiroidectomia nu este corespunzătoare din punct de vedere clinic sau este contraindicat.

Euroopan unioni - romania - EMA (European Medicines Agency)

janssen-cilag international nv - doripenemul - pneumonia, ventilator-associated; pneumonia, bacterial; urinary tract infections; bacterial infections; cross infection - antibacteriene pentru uz sistemic, - doribax este indicat pentru tratamentul următoarelor infecții la adulți:pneumonie nosocomială (inclusiv ventilator-associated pneumonia);infecții intra-abdominale complicate;infecții complicate ale tractului urinar. trebuie luate în considerare ghidurile oficiale referitoare la utilizarea adecvată a medicamentelor antibacteriene.